Anagrelide is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
FDA,2021.10
Anagrelide, as a platelet-reducing medication, plays an important role in the tr···【more】
Release date:2026-03-27Recommended:103
Anagrelide is used to reduce the platelet count in patients with myeloproliferat···【more】
Release date:2026-01-30Recommended:106
Thrombocythemia【more】
Release date:2026-01-05Recommended:87
LuciusVersionofAnagrelide:DosageandAdministration,Indications,PrecautionsIndicat···【more】
Release date:2025-12-02Recommended:153
Anagrelide is a drug used to treat thrombocythemia, primarily for abnormal eleva···【more】
Release date:2024-12-12Recommended:292